The management of recurrent/refractory (R/R) Hodgkin lymphoma (HL) remains challenging.
Previously published data have shown some efficacy of rituximab in this setting. The …

H odgkin's lymphoma is unusual among cancers in that it consists of a small number of
malignant H odgkin/R eed–S ternberg cells in a sea of immune system cells, including T …

Background. Even though Hodgkin lymphoma is a highly curable disease, some of the
patients have either a refractory disease or experience a relapse following a successful …

Благодаря стремительным успехам в развитии онкогематологии за полвека лимфома
Ходжкина (ЛХ) превратилась из фатального в наиболее курабельное …

Abstract Approximately 5–10% of patients with Hodgkin lymphoma are refractory to initial
treatment. The aim of our study was to assess the clinico-epidemiological profile, prognostic …

В отличие от большинства злокачественных опухолей при лимфоме Ходжкина (ЛХ)
возможность излечения сохраняется и у больных, опухоли которых не ответили на …

Лимфома Ходжкина (ЛХ)–это злокачественное опухолевое заболевание
лимфатической системы. Впервые как самостоятельное заболевание, а не как …

LE LYMPHOME DE HODGKIN EN RECHUTE/RÉFRACTAIRE : PROFIL
ÉPIDÉMIOLOGIQUE, CLINIQUE, PARACLINIQUE, PRONOSTIQUE ET THÉRAPEUTIQUE …

Mediastinal gray zone lymphoma (MGZL) is an extremely rare type of Non-Hodgkin
lymphoma with a predominance in young men [1]. This disease exhibits transitional features …

Background: Programmed death 1 blockade via pembrolizumab monotherapy has
demonstrated favourable anti-tumor activity and toxicity in patients with relapsed/refractory …